Rockwell Medical revealed on 26 January it had won approval from the FDA to market Triferic (ferric pyrophosphate) as a replacement of iron to maintain hemoglobin in adults with hemodialysis-dependent chronic kidney disease.
The company, however, failed to win a second indication of reducing the use of erythropoiesis stimulating agents (ESAs) required to...